M4 muscarinic receptor Inhibitors
1 drugsAbout M4 muscarinic receptor
The M4 muscarinic receptor is a G protein-coupled receptor that binds acetylcholine, modulating central and peripheral nervous system activity. It plays diverse roles in neurotransmission and cellular signaling pathways.
Currently, there is no genetic evidence directly linking the M4 muscarinic receptor to specific diseases, limiting confidence in target validation.
One FDA-approved drug, darifenacin, targets muscarinic receptors and was first approved in 2017. It is a small molecule drug marketed by MACLEODS PHARMS LTD.
Top M4 muscarinic receptor Drugs
MACLEODS PHARMS LTD is the only company with an approved drug targeting muscarinic receptors.
Low competitive intensity may present an opportunity for new entrants, but also indicates potential challenges in market viability.
M4 muscarinic receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets M4 muscarinic receptor, using small molecule modality.
Explore opportunities for novel modalities like antibodies or peptides to differentiate from existing treatments.
M4 muscarinic receptor Clinical Trials 8 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on M4 muscarinic receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 2 | 0 | 1 | 1 | 0% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M4 muscarinic receptor Drug Approval Timeline (2017 - 2017)
Darifenacin was first approved in 2017 and remains the most recent approval.
The lack of recent approvals suggests a potentially saturated market or challenges in developing new M4-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on M4 muscarinic receptor. A trial counts if an approved drug acting on M4 muscarinic receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.